Cetuximab
Advanced Esophageal Adenocarcinoma
BeOne Medicinesmonoclonal_antibodyPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
47 Active assets in the Advanced Esophageal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin I-Mab Biopharma US Limited | Phase 3 | BB |
Capecitabine I-Mab Biopharma US Limited | Phase 3 | B |
Tislelizumab BeOne Medicines | Phase 3 | B |
Durvalumab University of California, Irvine | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | B |
View all 50 →
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →